Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC_EX:A61K39/42

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/132346COMBINATION HBV THERAPY
WO 25.06.2020
Int.Class A61K 31/713
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
713Double-stranded nucleic acids or oligonucleotides
Appl.No PCT/US2019/067643 Applicant VIR BIOTECHNOLOGY, INC. Inventor BAKARDJIEV, Anna
The present disclosure provides methods for treating HBV infection using combination therapies, and related kits and compositions for use. The components of the combination therapies include an inhibitor of HBV gene expression or an agent that reduces HBV antigenic load, and an anti-HBV antibody.
2.WO/2020/132214EBOLA VIRUS GLYCOPROTEIN-SPECIFIC MONOCLONAL ANTIBODIES AND USES THEREOF
WO 25.06.2020
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/US2019/067423 Applicant THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Inventor SULLIVAN, Nancy J.
Human monoclonal antibodies that specifically bind Ebola virus glycoprotein with nanomolar affinity are described. The monoclonal antibodies were isolated by bulk sorting of plasmablasts from a human Ebola virus vaccinee and pairing of the immunoglobulin heavy and light chain genes using emulsion PCR. The paired immunoglobulin genes were expressed using Fab yeast display to screen and characterize the antibodies. The Ebola virus-specific monoclonal antibodies can be used, for example, to diagnose and treat Ebola virus infection or Ebola virus disease in a subject.
3.20200200749ANTIBODY-MEDIATED NEUTRALIZATION OF EBOLA VIRUSES
US 25.06.2020
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No 16790658 Applicant VANDERBILT UNIVERSITY Inventor James E. CROWE, Jr.

The present disclosure is directed to antibodies binding to and neutralizing ebolavirus and methods for use thereof. The present disclosure is directed to a method of detecting an ebolavirus infection in a subject comprising (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Table 2, or an antibody fragment thereof; and (b) detecting ebolavirus glycoprotein in said sample by binding of said antibody or antibody fragment to antigen in said sample. In still further embodiments, the present disclosure concerns immunodetection kits for use with the iminunodetection methods described above.

4.20200199204Broadly Neutralizing Monoclonal Antibodies Against HIV-1 V1V2 Env Region
US 25.06.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 16718322 Applicant The United States of America, as represented by the Secretary, Department of Health and Human Servic Inventor Chaim Aryeh Schramm

The present invention relates anti-HIV therapies and prophylaxis. Specifically, the invention relates to broadly neutralizing antibodies against HIV-1, nucleic acids encoding these antibodies, vectors comprising the nucleic acids and cells and pharmaceutical compositions Comprising said vectors and/or antibodies. The present invention also relates to use of the antibodies and/or vectors for the treatment and/or prevention of HIV-1 infection in a subject. Furthermore, the invention also relates to a kit containing the antibodies of the invention.

5.WO/2020/132493COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING HIV-INFECTION AND/OR A RELATED CLINICAL CONDITION THEREOF
WO 25.06.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2019/067936 Applicant CLAUSS, Matthias Alexander Inventor CLAUSS, Matthias Alexander
Therapeutic compositions comprising one or more agents that inhibit the Nef-PAK2 interface, and methods of administering those therapeutic compositions to model, treat, reduce resistance to treatment, prevent, and diagnose a condition/disease associated with HIV-infection or a related clinical condition thereof, are disclosed.
6.WO/2020/129068ANTI-HEPATITIS C VIRUS ANTIBODIES
WO 25.06.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/IL2019/051392 Applicant BAR ILAN UNIVERSITY Inventor GAL-TANAMY, Meital
The present invention concerns isolated monoclonal antibodies or any antigen-binding fragment thereof which bind to hepatitis C virus E2 protein (HCV E2). In particular the invention concerns neutralizing anti HCV E2 antibodies, and their use for treating HCV infection. Furthermore, the invention concerns methods for preparing neutralizing anti HCV scFv antibodies associated with HCV clearance.
7.WO/2020/119663ANTI-H7N9 FULLY HUMAN MONOCLONAL ANTIBODY 4E18, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
WO 18.06.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2019/124191 Applicant SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY CHINESE ACADEMY OF SCIENCES Inventor WAN, Xiaochun
An anti-H7N9 fully human monoclonal antibody 4E18, a preparation method therefor, and an application thereof. Fully human monoclonal antibody 4E18 without containing any murine components is quickly screened by using memory B cells and a PCR method. The antibody can target hemagglutinin (HA) that binds to H7N9 viruses, and has neutralizing activity against H7N9 virus infection; no human anti-mouse antibody reaction would occur, and better biocompatibility is provided.
8.20200190167POLYOMAVIRUS NEUTRALIZING ANTIBODIES
US 18.06.2020
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
Appl.No 16657855 Applicant Novartis AG Inventor Johanna ABEND

The present invention relates to anti-VP1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.

9.WO/2020/119664FULLY HUMAN ANTI-H7N9 MONOCLONAL ANTIBODY 2G3, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
WO 18.06.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2019/124192 Applicant SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY CHINESE ACADEMY OF SCIENCES Inventor WAN, Xiaochun
Provided are a fully human anti-H7N9 monoclonal antibody 2G3, a preparation method therefor and an application thereof. The antibody can targetedly bind to hemagglutinin (HA) of an H7N9 virus and has significant neutralizing activity against an H7N9 viral infection. The antibody has no toxic side effects, such as a human anti-mouse antibody response, has good biocompatibility, and is suitable for potential use as a macromolecular drug to treat the influenza virus.
10.WO/2020/119666ANTI-H7N9 FULLY HUMAN MONOCLONAL ANTIBODY 3F12, PREPARATION METHOD THEREFOR AND USE THEREOF
WO 18.06.2020
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2019/124218 Applicant SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY CHINESE ACADEMY OF SCIENCES Inventor WAN, Xiao Chun
Provided are an anti-H7N9 fully human monoclonal antibody 3F12, a preparation method therefor and use thereof. Said antibody can target hemagglutinin HA binding to H7N9 virus, and has significant neutralization activity against H7N9 viral infection. Said antibody does not produce toxic side effects such as anti-mouse antibody reaction, and has better biocompatibility, being more suitable and more potential to be a macromolecular drug for treating influenza virus.